Give Online: Help shape patient care for generations to come.


Request an Appointment

Cancer Answer Line:

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

ASNA 1815 15-979 A Phase 1/2, open-label, uncontrolled, multiple dose escalation, cohort expansion and extension study to evaluate the safety, tolerability, and pharmacokinetics of ASN001 in subjects with metastatic progressive castrate resistant prostate cancer. Main Campus Phase 1, Phase 2Prostate
CASE 3815 15-387 The effectiveness of a proposed Prostate Cancer outreach program in a predominantly African American community that promotes informed decision-making for prostate cancer screening and utilizes community navigation Main Campus  Prostate
CASE 5815 16-396 The Association between HSD3B1 Genotype and Steroid Metabolism in Normal and Prostate Cancer Tissue of Men with Intermediate and High-risk Prostate Cancer Undergoing Radical Prostatectomy after Treatment with ARN-509 and Leuprolide. Main Campus  Prostate
CASE 6Y14 15-465 Integrated 3D x-ray and ultrasound Guided Radiation Therapy of Soft Tissue Target Main Campus  Liver, Pancreas, Prostate
CASE 781313-661 The origins of resistance to hormonal therapy in advanced prostate cancer Main Campus  Prostate
INVO 1815 16-394 Phase I, Open-label Trial to Evaluate the Safety and Immunogenicity of INO-5150 alone or in combination with INO-9012 in Men with Biochemically relapsed (PSA) Prostate Cancer Main Campus Phase 1Prostate
JHU 1815 15-1068 A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer Main Campus Phase 2Prostate
LILY 1816 16-787 A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer Main CampusAdvanced/MetastaticPhase 2Prostate
NRG BR001 15-695 A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases Main Campus Phase 1Breast, Lung, NSCLC (Non-small cell lung cancer), Prostate
OCOP 181414-1317 A Multinational, Randomised, Double-Blind, Placebo-Controlled, Phase III Efficacy and Safety Study of ODM-201 in Men with High-Risk Non- Metastatic Castration-Resistant Prostate Cancer (ARAMIS) Main Campus Phase 3Prostate
RTOG 0924CC16-475 Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: a phase III randomized trial Fairview, Florida Weston, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, Strongsville, Wooster Phase 3Prostate

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).


Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.